WO2005046667A3 - System a transport inhibitors for treating or preventing neuropsychiatric disorders - Google Patents

System a transport inhibitors for treating or preventing neuropsychiatric disorders Download PDF

Info

Publication number
WO2005046667A3
WO2005046667A3 PCT/US2004/036934 US2004036934W WO2005046667A3 WO 2005046667 A3 WO2005046667 A3 WO 2005046667A3 US 2004036934 W US2004036934 W US 2004036934W WO 2005046667 A3 WO2005046667 A3 WO 2005046667A3
Authority
WO
WIPO (PCT)
Prior art keywords
transport inhibitors
treating
neuropsychiatric disorders
disorders
preventing neuropsychiatric
Prior art date
Application number
PCT/US2004/036934
Other languages
French (fr)
Other versions
WO2005046667A2 (en
Inventor
Daniel C Javitt
Henry Sershen
Original Assignee
Res Found Mental Hygiene
Daniel C Javitt
Henry Sershen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Mental Hygiene, Daniel C Javitt, Henry Sershen filed Critical Res Found Mental Hygiene
Publication of WO2005046667A2 publication Critical patent/WO2005046667A2/en
Publication of WO2005046667A3 publication Critical patent/WO2005046667A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to System A transport inhibitors, antagonists, derivatives, or mimetics thereof, and their use as compounds, drugs, or agents for the treatment or prevention of neuropsychiatric diseases, disorders, or conditions, including schizophrenia. Preferred compounds include 2-methyl-aminobutyric acid and clozapine. Another embodiment of the invention relates to methods of identifying or screening for such System A transport inhibitors for the treatment or prevention of neuropsychiatric diseases, disorders, or conditions.
PCT/US2004/036934 2003-11-07 2004-11-05 System a transport inhibitors for treating or preventing neuropsychiatric disorders WO2005046667A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51824703P 2003-11-07 2003-11-07
US60/518,247 2003-11-07

Publications (2)

Publication Number Publication Date
WO2005046667A2 WO2005046667A2 (en) 2005-05-26
WO2005046667A3 true WO2005046667A3 (en) 2006-03-02

Family

ID=34590240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036934 WO2005046667A2 (en) 2003-11-07 2004-11-05 System a transport inhibitors for treating or preventing neuropsychiatric disorders

Country Status (1)

Country Link
WO (1) WO2005046667A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
JP2009523802A (en) * 2006-01-17 2009-06-25 リージェンツ オブ ザ ユニバーシティー オブ コロラド Central administration of stable preparations of therapeutic agents for CNS conditions
FR2935611B1 (en) * 2008-09-10 2010-10-15 Commissariat Energie Atomique USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010196A2 (en) * 2000-07-28 2002-02-07 Merck Patent Gmbh Identification of a novel glutamine transporter
WO2002012340A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporters and ion channels
WO2002040541A2 (en) * 2000-10-27 2002-05-23 Incyte Genomics, Inc. Transporters and ion channels
WO2003008621A2 (en) * 2001-07-17 2003-01-30 Millennium Pharmaceuticals, Inc. 87144, human amino acid transporter family member and uses therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010196A2 (en) * 2000-07-28 2002-02-07 Merck Patent Gmbh Identification of a novel glutamine transporter
WO2002012340A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporters and ion channels
WO2002040541A2 (en) * 2000-10-27 2002-05-23 Incyte Genomics, Inc. Transporters and ion channels
WO2003008621A2 (en) * 2001-07-17 2003-01-30 Millennium Pharmaceuticals, Inc. 87144, human amino acid transporter family member and uses therefor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALBERS A ET AL: "Na+ transport by the neural glutamine transporter ATA1.", PFLUGERS ARCHIV : EUROPEAN JOURNAL OF PHYSIOLOGY. OCT 2001, vol. 443, no. 1, October 2001 (2001-10-01), pages 92 - 101, XP008046744, ISSN: 0031-6768 *
DUNCAN L ET AL: "Clozapine inhibits rat brain synaptosomal glycine transport via blocakade of system A transport: implication for treatment of schizophrenia.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 580.4 URL - http://sf, XP008046496 *
LANGEN K-J ET AL: "Transport of cis- and trans-4-[<18>F]fluoro-L-proline in F98 glioma cells", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 29, no. 6, August 2002 (2002-08-01), pages 685 - 692, XP004381417, ISSN: 0969-8051 *
MACKENZIE B. ET AL: "Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family.", PFLUEGERS ARCHIV EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 447, no. 5, February 2004 (2004-02-01), pages 784 - 795, XP002345200 *
PURI B K ET AL: "Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder", BRITISH JOURNAL OF CLINICAL PRACTICE, vol. 49, no. 6, November 1995 (1995-11-01), pages 333 - 334, XP002122087, ISSN: 0007-0947 *
THE FRENCH CLOZAPINE PARKINSON STUDY GROUP: "Clozapine in drug-induced psychosis in Parkinson's disease", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 353, no. 9169, June 1999 (1999-06-01), pages 2041 - 2042, XP004831159, ISSN: 0140-6736 *
TRAVIS M J ET AL: "5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine", BRITISH JOURNAL OF PSYCHIATRY, HEADLEY BROTHERS, ASHFORD, GB, vol. 173, 1998, pages 236 - 241, XP002953286, ISSN: 0007-1250 *
WATANABE Y ET AL: "[Delusional depression]", NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE. AUG 2001, vol. 59, no. 8, August 2001 (2001-08-01), pages 1546 - 1549, XP008046716, ISSN: 0047-1852 *
YAO D ET AL: "A novel system A isoform mediating Na+/neutral amino acid cotransport", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, & 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 619.10, XP008046729, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
WO2005046667A2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
IL184353A0 (en) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl)methanone derivatives as glycine transporter 1 (glyt-1)inhibitors for the treatment of neurological and neuropsychiatric disorders
ATE534391T1 (en) 3,11B-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF PSYCHOSES
TWI341201B (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BRPI0417697A (en) heterocyclic aspartyl protease inhibitors
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
EP1589969A4 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EP1578414A4 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2006042137A3 (en) Methods for identifying parkinson&#39;s disease therapeutics
WO2006067414A3 (en) Glycine transport inhibitors
WO2003037310A3 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
NO20080037L (en) Combination of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
DE60317098D1 (en) CARBOSTYRIL DERIVATIVES WITH SELECTIVE SEROTONIN INHIBITORS FOR THE TREATMENT OF MENTAL DISEASES
WO2005046667A3 (en) System a transport inhibitors for treating or preventing neuropsychiatric disorders
WO2003066004A3 (en) Therapeutic compounds
EA200601592A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR
WO2003105891A3 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
ATE425756T1 (en) USE OF CARBAMAZEPINE DERIVATIVES TO TREAT AGITATIO IN DEMENTIA PATIENTS
WO2004112690A3 (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase